UCB SA (OTCMKTS:UCBJY) Short Interest Down 76.3% in March

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 3,200 shares, a decrease of 76.3% from the March 15th total of 13,500 shares. Based on an average daily trading volume, of 45,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company's stock are short sold.

UCB Stock Up 0.8 %

OTCMKTS UCBJY traded up $0.64 during mid-day trading on Friday, reaching $77.90. The stock had a trading volume of 41,154 shares, compared to its average volume of 43,559. UCB has a 1 year low of $63.58 and a 1 year high of $106.60. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company has a fifty day moving average price of $91.36 and a 200 day moving average price of $94.54.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.